$0.70
1.04%
Nasdaq, Fri, Oct 02 2026.
ISIN
US44148G1058
Symbol
HOTH

Hoth Therapeutics, Inc. Stock price

$0.70
+0.01 0.91% 1M
+0.14 24.17% 6M
-0.29 29.53% YTD
-0.86 55.28% 1Y
-0.79 53.17% 3Y
-28.30 97.59% 5Y
-212.55 99.67% 10Y
-212.55 99.67% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.01 1.04%
ISIN
US44148G1058
Symbol
HOTH
Industry

Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$4.1m
Shares outstanding
16.3m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Financial Health
Equity Ratio
80.9%
Return on Equity
-202.7%
ROCE
-277.3%
ROIC
-
Debt/Equity
0.0
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-11.5m
Net Income
$-11.7m
Free Cash Flow | ex SBC
$-10.1m | -
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-19.7%
Net Income
-21.5%
Free Cash Flow
-25.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.7
FCF per Share
$-0.6
Short interest
4.3%
Employees
3
Rev per Employee
$0.0

Hoth Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Hoth Therapeutics, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Hoth Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Hoth Therapeutics, Inc.

Mar '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.03 6.03
23% 23%
-
- Research and Development Expense 5.51 5.51
16% 16%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
20% 20%
-
Net Profit -12 -12
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hoth Therapeutics, Inc. Stock News

Neutral
PRNewsWire
●
4 months ago
Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architecture Designed for Ultra-Low-Power, Radiation-Tolerant Computing in Space and Defense Applications HOBOKEN, N.J., May 27, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company") today announced that, following the strategic repositioning disclosed on May 19, 2026, it h...
Neutral
PRNewsWire
●
4 months ago
Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell Program HOBOKEN, N.J., May 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a clinical-stage biopharmaceutical compa...
Neutral
PRNewsWire
●
5 months ago
Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spintronic Computing Technologies for AI, Defense, and Space Applications HOBOKEN, N.J., May 19, 2026 /PRNewswire/ -- (NASDAQ: HOTH) ("Hoth" or the "Company") today announced that it intends to change its name to Rocket One, Inc. ("Rocket One"), and to restructure its business to position the Compan...
More Hoth Therapeutics, Inc. News

Company Profile

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

Head office United States
CEO Mr. Knie
Employees 3
Founded 2017
Website hoththerapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today